213 related articles for article (PubMed ID: 11367559)
21. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platform.
Chen Z; Yan Y; Munshi S; Li Y; Zugay-Murphy J; Xu B; Witmer M; Felock P; Wolfe A; Sardana V; Emini EA; Hazuda D; Kuo LC
J Mol Biol; 2000 Feb; 296(2):521-33. PubMed ID: 10669606
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
23. The integrase of the human immunodeficiency virus as a novel target for the antiviral therapy of AIDS.
Witvrouw M; Debyser Z
Verh K Acad Geneeskd Belg; 2003; 65(5):325-34. PubMed ID: 14671848
[TBL] [Abstract][Full Text] [Related]
24. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.
Goldgur Y; Craigie R; Cohen GH; Fujiwara T; Yoshinaga T; Fujishita T; Sugimoto H; Endo T; Murai H; Davies DR
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13040-3. PubMed ID: 10557269
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
26. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
Molteni V; Greenwald J; Rhodes D; Hwang Y; Kwiatkowski W; Bushman FD; Siegel JS; Choe S
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):536-44. PubMed ID: 11264582
[TBL] [Abstract][Full Text] [Related]
27. New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.
Corona A; di Leva FS; Rigogliuso G; Pescatori L; Madia VN; Subra F; Delelis O; Esposito F; Cadeddu M; Costi R; Cosconati S; Novellino E; di Santo R; Tramontano E
Antiviral Res; 2016 Oct; 134():236-243. PubMed ID: 27659398
[TBL] [Abstract][Full Text] [Related]
28. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids.
Zhu K; Cordeiro ML; Atienza J; Robinson WE; Chow SA
J Virol; 1999 Apr; 73(4):3309-16. PubMed ID: 10074185
[TBL] [Abstract][Full Text] [Related]
29. Design of novel bioisosteres of beta-diketo acid inhibitors of HIV-1 integrase.
Sechi M; Sannia L; Carta F; Palomba M; Dallocchio R; Dessì A; Derudas M; Zawahir Z; Neamati N
Antivir Chem Chemother; 2005; 16(1):41-61. PubMed ID: 15739621
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
[TBL] [Abstract][Full Text] [Related]
31. HIV integrase: a target for drug discovery.
Lutzke RA; Plasterk RH
Genes Funct; 1997 Dec; 1(5-6):289-307. PubMed ID: 17366700
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases.
Maignan S; Guilloteau JP; Zhou-Liu Q; Clément-Mella C; Mikol V
J Mol Biol; 1998 Sep; 282(2):359-68. PubMed ID: 9735293
[TBL] [Abstract][Full Text] [Related]
33. Similarities in the HIV-1 and ASV integrase active sites upon metal cofactor binding.
Lins RD; Straatsma TP; Briggs JM
Biopolymers; 2000 Apr; 53(4):308-15. PubMed ID: 10685051
[TBL] [Abstract][Full Text] [Related]
34. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
35. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
36. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations.
Bujacz G; Jaskólski M; Alexandratos J; Wlodawer A; Merkel G; Katz RA; Skalka AM
Structure; 1996 Jan; 4(1):89-96. PubMed ID: 8805516
[TBL] [Abstract][Full Text] [Related]
37. [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].
Mirambeau G
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():11-6. PubMed ID: 19572420
[TBL] [Abstract][Full Text] [Related]
38. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "killing two birds with one stone".
Andréola ML
Curr Pharm Des; 2004; 10(30):3713-23. PubMed ID: 15579066
[TBL] [Abstract][Full Text] [Related]
39. New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity.
Normand-Bayle M; Bénard C; Zouhiri F; Mouscadet JF; Leh H; Thomas CM; Mbemba G; Desmaële D; d'Angelo J
Bioorg Med Chem Lett; 2005 Sep; 15(18):4019-22. PubMed ID: 16002283
[TBL] [Abstract][Full Text] [Related]
40. Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors.
Reddy KK; Singh SK
Chem Biol Interact; 2014 Jul; 218():71-81. PubMed ID: 24792351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
